biostudies-literatureUnknown11(1)Choi HAdoptive transfer of γδ T cells is a novel immunotherapeutic approach to glioblastoma. Few recent studies have shown the efficacy of γδ T cells against glioblastoma, but no previous studies have identified the ligand-receptor interactions between γδ T cells and glioblastoma cells. Here, we identify those ligand-receptor interactions and provide a basis for using γδ T cells to treat glioblastoma. Vγ9Vδ2 T cells were generated from peripheral blood mononuclear cells of healthy donors using artificial antigen presenting cells. MICA, ULBP, PVR and Nectin-2 expression in 10 patient-derived glioblastoma (PDG) cells were analyzed. The in vitro cytokine secretion from the γδ T cells and their cytotoxicity toward the PDG cells were also analyzed. The in vivo anti-tumor effects were evaluated using Oncoimmunology2138152https://www.ebi.ac.uk/biostudies/studies/S-EPMC9629076biostudies-literatureHuman allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands.PMC9629076Kim TGPark SAPark JPark JHChoi HJeun SSLee HKLee YAhn SLee JHfalseHuman allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands.Adoptive transfer of γδ T cells is a novel immunotherapeutic approach to glioblastoma. Few recent studies have shown the efficacy of γδ T cells against glioblastoma, but no previous studies have identified the ligand-receptor interactions between γδ T cells and glioblastoma cells. Here, we identify those ligand-receptor interactions and provide a basis for using γδ T cells to treat glioblastoma. Vγ9Vδ2 T cells were generated from peripheral blood mononuclear cells of healthy donors using artificial antigen presenting cells. MICA, ULBP, PVR and Nectin-2 expression in 10 patient-derived glioblastoma (PDG) cells were analyzed. The in vitro cytokine secretion from the γδ T cells and their cytotoxicity toward the PDG cells were also analyzed. The in vivo anti-tumor effects were evaluated using 2022-01-01T00:00:00Z20222025-04-27T01:49:50.915Z2025-04-06T18:20:50.527ZS-EPMC96290763633814710.1080/2162402X.2022.2138152